WILLIAM BOYD: Open Payments
NPI 1982143228 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$566 in 27 payments from 10 companies in 2025. Trend: 2023 $603 · 2024 $963 · 2025 $566
Food & beverage: $566
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $203 |
| Novartis Pharmaceuticals Corporation | 4 | $82 |
| PFIZER INC. | 4 | $82 |
| Amgen Inc. | 2 | $43 |
| UCB, Inc. | 1 | $40 |
| LANTHEUS MEDICAL IMAGING, INC. | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Janssen Biotech, Inc. | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
Products named: UBRELVY, KESIMPTA, ELIQUIS, UPLIZNA, Rystiggo, BOTOX, DALVANCE, DEFINITY.
Industry payments across AL — which companies pay providers there.
